Most uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...
Acrivon Therapeutics shares new trial data showing strong cancer responses, early tumor shrinkage, and pipeline progress, ...
Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) ...
Epidemiological profile of Ophir Loyola Cancer Hospital: A snapshot of the incidence of solid neoplasms in the eastern Amazon. Patterns and trends in incidence, survival, and treatment among patients ...
Researchers say that in the course of developing a new model for ovarian cancer, they've developed additional evidence that serous uterine cancer possibly begins in the fallopian tubes, not the uterus ...
Investing.com -- Acrivon Therapeutics Inc (NASDAQ:ACRV) stock plummeted 29.2% Thursday after the clinical-stage biotech company released mixed results from its ongoing cancer treatment trials.
Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331 Uterine serous carcinoma (USC) is a distinct ...
Expert Rev Anticancer Ther. 2012;12(1):41-49. © 2012 Expert Reviews Ltd. Uterine serous cancer (USC) is a highly aggressive variant of endometrial cancer. USC is ...
Most uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback